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Abstract
Dengue is a disease caused by the dengue virus (DENV), being the most important
arbovirus in the world. About 3.97 billion people live in countries at risk and 400 million
infections occur each year, of which 500,000 suffer from the most severe form of the
disease and 25,000 of these die. The clinical spectrum of Dengue ranges from asymptom-
atic infection to severe Dengue characterized by increased vascular permeability, bleeding
disorders, shock, and death. The increase in global cases of this disease is due in part to the
absence of effective public intervention measures and lack of a specific treatment and
vaccines licensed for human use. Therefore, in this review, we will present the different
strategies known to date for the development of vaccines for this disease, as well as the
results and limitations obtained in the different clinical studies.
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1. Introduction
Dengue is a mosquito-borne viral disease caused by four types of dengue viruses, which, in the
recent years, has rapidly become widespread worldwide. Dengue virus transmission is attrib-
uted to female mosquitoes of the species Aedes aegypti, in the majority of cases, as well as Ae.
albopictus to a lesser extent. Other diseases that are transmitted by this mosquito include
chikungunya, yellow fever, and Zika infection [1]. Dengue is a very rapidly growing public
health problem being currently faced by approximately 40% of the global population living in
more than a hundred tropical and subtropical countries [2]. Dengue is widespread throughout
the tropics, with local variations in risk influenced by rainfall, temperature as consequence of
climate change, unplanned rapid urbanization, unprecedented population growth, increasing
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movement of people (and consequently viruses), international travel and breakdown in public
health infrastructure, and vector control programs. The actual numbers of dengue cases are
underreported and many cases are misclassified. The prevalence of dengue is estimated at 3.9
billion people who are at risk of infection in 128 tropical and subtropical countries, mainly
southeast and south Asia, Central and South America, and the Caribbean. A recent estimate
indicates 390 million dengue infections per year (95% credible interval 284–528million), of which
96 million (67–136 million) manifest clinically (with any severity of disease), with an estimated
500,000 cases each year of life-threatening disease in the form of severe dengue—including
dengue hemorrhagic fever and dengue shock syndromemostly in the pediatric population, with
about 20,000 succumbing to it, and is the leading cause of childhood death in many countries [1–
3]. Dengue is associated with considerable social, economic, and political consequences caused
by urban epidemics, such as those seen in Delhi (1996), Cuba (1977–1979 and 1997), Taiwan
(2002), and Brazil (2008). Furthermore, Dengue is currently also a major cause of morbidity in
American and European travelers and military personnel [4]. This disease places a high eco-
nomic burden on both governments and individuals; for instance, in America, Dengue illness
costs US$2.1 billion per year on average, excluding vector control, exceeding costs of other viral
illnesses. In addition, in Southeast Asia, there is an estimate of 2.9 million dengue episodes and
5906 deaths annually, with an annual economic burden of $950 million [3].
2. Natural clinical evolution
Dengue virus infections encompass a range of well-described clinical illnesses ranging from
an asymptomatic infection to a self-limiting febrile illness, dengue fever, to severe dengue
(shock and death), a clinical syndrome that typically presents with capillary permeability and
can lead to dengue shock syndrome and dengue hemorrhagic fever. Among less common
presentations of severe dengue are encephalitis, hepatitis, and renal dysfunction [4]. Infection
by any dengue virus requires a 4- to 8-day incubation period and can produce a wide spectrum
of illnesses, the majority of these being asymptomatic or subclinical. Although most patients
are able to recover after a self-limiting (yet debilitating) illness, a small proportion develops a
severe form of the disease, which is mainly characterized by plasma leakage with or without
bleeding [3]. The acute illness is usually benign and self-limiting. Moreover, a secondary
infection, corresponding to a subsequent infection with a different serotype is also character-
ized by acute fever and several other nonspecific signs and symptoms, usually indistinguish-
able from a range of other illnesses. However, in 2–3% of secondary infections with another
serotype there is a higher risk of increased disease severity, causing life-threatening Dengue
with Warning Signs (DWS+) and Severe dengue (SD), according to the revised WHO dengue
case classification (DENCO) [2, 5]. Serotype-cross-reactive antibodies facilitate DENV infection
in Fc-receptor-bearing cells by promoting virus entry via Fcγ receptors (FcγR), a process
known as antibody-dependent enhancement (ADE) [6, 7]. Dengue without Warning Signs
(DWS) is more often observed in adults and adolescents and can manifest with only a mild
fever only or a more disabling disease. This latter form is characterized by symptoms occurring
mainly in the early febrile stage, such as the sudden onset of high fever, severe headache, retro-
orbital pain, myalgia, arthralgia, and rash. In the critical phase, the skin is flushed with the
appearance of a petechial rash, occurring predominantly around the time of defervescence,
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when an increase in capillary permeability accompanied by increased hematocrit can occur,
leading to hypovolemic shock that can result in organ impairment, metabolic acidosis, dissem-
inated intravascular coagulation, and severe hemorrhage. If untreated, mortality can be
as high as 20%, whereas appropriate case management and intravenous rehydration can
reduce mortality to less than 1% [3]. SD usually affects children younger than 15 years of
age, although it can occur in adults. SD is characterized by a transient increase in vascular
permeability resulting in plasma leakage with high fever, bleeding, thrombocytopenia, and
hemoconcentration, which can lead to shock [5]. Two factors, namely, antibody-dependent-
enhancement (ADE) and inherent virulence of the DEN viruses, appear to contribute the most
to disease pathogenesis [2].
3. Pathogenesis of Dengue virus infection
The pathophysiological basis for severe dengue is multifactorial, resulting from a complex
interaction between the virus, the host, and, at least in part, immune-mediated mechanisms.
Individuals with primary Dengue virus infection induce a lifelong protective immunity to the
infecting serotype, accompanied by a short-term cross-immunity against other serotypes and
development only leads to self-limited dengue fever characterized by high fever and debilitat-
ing joint pain, recovery from infection by one provides lifelong immunity against that sero-
type. However, subsequent infection with a different dengue serotype is more likely to cause
DWS+/SD, and cross-immunity to the other serotypes after recovery is only partial and tem-
porary. Epidemiological data suggest an increased risk of DWS+/SD in people with preexisting
heterotypic dengue virus antibodies, and this has led to research in dengue pathogenesis
focusing on the subsequent infections by other serotypes and an increased risk of developing
severe dengue. Accordingly, antibodies against a given serotype can cross-react with, but not
cross-protect against, the remaining three virus serotypes [4] during secondary infections.
Immunopathological mechanisms have been proposed, such as the immune system improve-
ment phenomenon (immunopotentiation), which contribute to the increased risk of DWS+ or
SD. It is widely accepted that these cross-reactive antibodies can promote enhanced uptake of
the heterologous virus into host cells, precipitating a hyperimmune reaction resulting in blood
vessel leakage and potentially fatal hypovolemic shock [1, 2]. This increase occurs when
nonneutralizing antibodies resulting from the primary infection favor the invasion of the
second virus with a different serotype into the target cells, a phenomenon known as anti-
body-dependent amplification or antibody-dependent enhancement (ADE) [8, 9]. Subsequent
infection with a different dengue serotype is more likely to cause DWS+/SD [8, 9]. According to
the ADE hypothesis, a primary infection with DENV produces an insufficient concentration of
antibodies or avidity to neutralize a secondary infection by DENV of a different serotype that
differs in its amino acid sequence by 30–35%; and these sub-neutralizing antibody concentra-
tions can promote infection in such cells by facilitating Fc-receptor-mediated entry [10]. These
concentrations could be enough to opsonize the secondary virus and target it for Fc-receptor-
mediated endocytosis into myeloid cells such as monocytes and macrophages (which consti-
tute the main site of DENV replication) and in this manner promote higher viral loads. ADE
can be observed in vitro and has also been proven to drive higher viral loads of DENV in
animal models [11]. The following findings support the hypothesis of the antibody-dependent
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enhancement (ADE): undiluted sera obtained early from patients with secondary infection was
shown to enhance dengue virus infection in vitro, infants born from dengue-immune mothers
displayed a higher viral burden than infants born to dengue nonimmune mothers and further
demonstrated immune activation associated with disease severity, and lethal antibody-
dependent enhancement has been shown in dengue mouse models, and virus-antibody com-
plexes bind to Fcγ receptor-bearing cells, resulting in increased infected cell mass and a rise in
viremia. The cardinal feature of DWS+ is plasma leakage believed to arise from pro-
inflammatory cytokine-inflicted damage to the vascular endothelium. Although the cause of
severe form of dengue infection is not clear, it has been revealed that secondary infection with
a different serotype of DENV, or even a homotypic reinfection, are major risk factors for SD
probably due to antibody-dependent enhancement. The phenomena of original antigenic sin,
as well as immune evasion that inhibits interferon (IFN)-α and IFN-β signaling by suppressing
Jak-Stat activation, a cytokine storm, and autoimmune responses are thought to contribute to
the pathogenesis of severe form of dengue disease [12, 13], see Figure 1. Dengue virus (DENV)
can inhibit both type I IFN production and signaling in susceptible human cells, including
dendritic cells (DCs). The proteolytic activity of the NS2B3 protease complex of DENVallows it
to function as an antagonist of type I IFN production. Other DENV proteins that antagonize
type I IFN signaling include NS2A, NS4A, NS4B, and NS5 by targeting different components
of this signaling pathway, such as STATs [15]. During a primary infection, serotype-specific as
well as cross-reactive memory T-cell responses are produced. On the other hand, during a
secondary dengue virus infection, viral epitopes expressed on infected cells trigger activation
of serotype-cross-reactive memory T-cells, with the production of pro-inflammatory cytokines.
The latter ultimately lead to plasma leakage in the vascular endothelium. The specific cellular
Figure 1. A hypothetical model of dengue pathogenesis. Viral and immunological factors contribute to clinical manifes-
tations, including severe hemorrhage, thrombocytopenia, plasma leakage, hepatomegaly, and neurological compromise.
DV: dengue virus. Adapted from Wan et al. [14].
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response against DENV begins with the activation of CD4+ T-cell during viremia and subse-
quently the activation of CD8+ T-cell. In individuals with DHF or DWS+ due to secondary
infections, the presence of CD4+/CD8+ memory T-cell and cytotoxic CD4+/CD8+ T-cell has
been demonstrated [16], and the activation of T-cell and the production of cytokines are
important factors in the pathogenesis of DWS+ [17]. Likewise, the cellular immune response,
in the case of DWS+, exacerbates the activation and release of cytokines, which is related to the
greater severity of the clinical picture. The activation of the complement system has also been
demonstrated in DHF, and high concentrations of C3 and C1q proteins can be detected in
severe cases. It is suggested that complex virus-circular antibodies could activate the cascade
reaction of the complement [18], see Figure 2. Regulatory immune pattern in homologous
versus a pro-inflammatory pattern in heterologous dengue virus secondary infection has been
reported. Several soluble factors produced by T cells, monocytes, macrophages, and mast cells
have been proposed to increase vascular permeability in primary endothelial cells. These
factors include TNFα, interleukin 6, interleukin 8, interleukin 10, interleukin 12, macrophage
migration inhibitory factor, HMGB1, MCP-1, and matrix metalloproteinases. Endothelial per-
meability can also be influenced by the maturation state of NS4B, which modulates the
cytokine response in monocytic cell lines. In addition, secreted NS1 protein, along with anti-
NS1 antibodies and complement activation, might be involved in dengue virus-induced vas-
cular leakage. Moreover, around defervescence, when plasma leakage is apparent, high levels
of complement activation products C3a and C5a are detected in plasma, followed by acceler-
ated consumption and large reduction of complement components in patients with dengue
shock syndrome. Activation of the complement system can stimulate the production of inflam-
matory cytokines associated with DWS+/SD, and trigger local and systemic effects implicated
Figure 2. Schematic representation of the immunopathogenesis of severe dengue disease. Adapted from Webster et al.
[4].
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in intravascular coagulation. Finally, although controversial, the role of autoimmunity in the
pathogenesis of dengue is mentioned, as autoantibodies resulting in platelet and endothelial
cell dysfunction might be involved in severe dengue pathogenesis. Not all cases of DWS+
occur in people who experience a secondary infection, since in some cases the virus’ own
virulence, added to the characteristics of the host, leads to the complication of the disease
[19], which may be due to the presence of antibodies against viral proteins that have cross-
reactivity with platelets and coagulation factors [18]. Certain nonstructural proteins such as
NS1, NS2, and NS3 appear to have a certain structural homology with coagulation factors,
platelets, integrins, and adhesins of human endothelial cells, allowing the activation of
autoreactive T lymphocytes that participate in the pathology of dengue [16, 20]. Anti-NS1
antibodies correlate with disease severity, and cross-reaction of anti-NS1 antibodies with liver
and endothelial cells are also implicated in affecting the integrity of the vascular endothelium
and platelets has been proposed to trigger these cells to express nitric oxide and undergo
apoptosis [2, 3, 14]. Certain antibodies to some E protein epitopes can bind to human plasmin-
ogen and inhibit plasmin activity (see Figure 3). Recently, it has been reported that Tropomy-
osin (TPM)-1 may play an important role in the pathogenesis of SD. It is plausible that the
elevation of TPM-1 in the plasma of SD patients can be due to excessive cell death, thereby
releasing TPM into the circulation as DAMPs, and leading to mast cell activation. Moreover,
the insulin pathway may play a role in the pathogenesis of SD, hence, regulating the insulin
Figure 3. A schematic model of autoantibody-mediated immunopathogenesis in DENV infection. Molecular mimicry
between platelets, endothelial cells, and coagulatory molecules with NS1, prM, E, and C proteins underlies the cross-
reactivity of anti-NS1, anti-prM, anti-E, and anti-C Abs, respectively, to host proteins. Abs Z antibodies; C Z capsid
protein; DENV Z dengue virus; E Z envelope protein; NS Z nonstructural protein; prM Z precursor membrane protein.
Adapted from Wan et al. [14].
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signaling pathway may be a key intervention to reduce plasma leakage in patients with SD
[12], see Figures 1–3.
A protective versus pathological outcome depends on the balance between the host’s genetic
and immunological background and viral factors. Vaccine development has been slowed by
fears that immunization might predispose individuals to the severe form of dengue infection
[3, 4]. There are four distinct, but closely related, serotypes of the virus that cause dengue
(DEN-1, DEN-2, DEN-3, and DEN-4).
No DENV-specific therapies are available, while a DENV vaccine that elicits protection in
people with prior DENV exposure but not in naive individuals and that is not equally protec-
tive against all four serotypes has recently begun to be licensed on a country-by-country basis.
This is mostly due to an incomplete understanding of the interplay between viral and host
factors that contribute to DENV pathogenesis. On the virus side, some DENV lineages are
more virologically and epidemiologically fit than others and are thus associated with DWS+/
SD manifestations. On the host side, DENV infection history is the primary determinant
associated with the development of more severe dengue disease, with potential contributions
from other factors such as genetic variation, age, and sex.
Several studies have demonstrated that DENV-specific antibodies can protect against infection
and, under certain conditions, enhance infection and disease severity, whereas the role of T
cells remains unclear. Thus, to avoid the risk of enhancement, a safe vaccine against dengue
virus will need to confer protective immunity against all four serotypes [10]. Consequently, the
adaptive immune response to dengue can be both protective and pathogenic, which compli-
cates vaccine development, as discussed in this chapter.
4. Dengue vaccines
Dengue virus is widespread throughout the tropics, representing an important, rapidly growing
public health problem with an estimated 2.5–3.9 billion people at risk of dengue fever and the
life-threatening severe dengue disease. Therefore, the need for a safe and effective vaccine for
dengue is immediate. Vaccine development has been slowed by fears that immunization might
predispose individuals to the severe form of dengue infection [4]. The characteristics and chal-
lenges that the ideal vaccine for the dengue virus must have are described in the following.
4.1. Characteristics of an ideal dengue vaccine and challenges to its development
4.1.1. Characteristics
• Safe in children and adults [3, 4]
• Avoids ADE (antibody-dependent enhancement) and pathogenesis
• Rapid immunization regime requiring a single vaccine or two that fit in with established
vaccine programs
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• Induces a balance between reactogenicity and immunogenicity
• Suitable for use in target age groups
• Genetically stable
• Stimulates neutralizing antibodies and Th1 cell-mediated immunity
• Induces long-lasting immunity, safety, and protection
• Generates neutralizing immunity to all four serotypes
• Does not contribute to immunopathogenesis (vaccine-induced enhancement)
• Easy storage and transportation
• Affordable and cost effective
4.1.2. Challenges
• Existing possibility of triggering ADE
• Vaccine must be tetravalent
• Dengue virus serotypes do not induce long-lasting heterotypic immunity
• No suitable or ideal animal model exists for immunization studies
• No well-established viral virulence markers are available
• Correlates of protection are not well defined
• Subsequent infection (especially, after a long-time interval) may lead to severe dengue
• Vaccine candidates should be evaluated in geographic areas with different transmission
patterns [3].
To date, there are several DENV vaccines under development, with some in phase 3 safety and
efficacy testing. These include inactivated, live attenuated, recombinant subunit, viral vec-
tored, and DNA vaccines. Dengue vaccine development has aimed to elicit a neutralizing
antibody response, as T cells are assumed to contribute a minor or secondary role in dengue
vaccine-mediated protection. Next, we will describe each of these vaccines.
4.2. Vaccine types
4.2.1. Live-attenuated virus (LAV)
The fundamental aim of vaccination is to promote protective immunity while avoiding disease
from the vaccine itself. The first generation of viral vaccines was based on empirical attenua-
tion by repeated passage in cultured cells. Several LAVs are eligible vaccines as they meet the
following criteria; they elicit a strong and protective immune response with a low risk of
disease from the vaccine itself. In the present regulatory environment, the use of LAVs has
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also been limited by safety concerns, including reversion to wild-type virulence. Because LAVs
are shed from vaccines, they sometimes present a risk to unvaccinated individuals with
impaired immunity. Although LAV vaccines have been developed for many RNA viruses, the
mutability of these pathogens presents unique challenges for vaccine design [21].
4.2.2. Purified inactivated virus (PIV)
It is widely believed that inactivated dengue virus vaccines are impractical given the difficulty
in obtaining sufficiently high titers of the virus in a suitable cell substrate. However, this was
challenged when dengue type-2 (dengue-2) virus was adapted to replicate to high titers in
certified Vero and fetal rhesus lung (FRhL-2) cell cultures and used to make prototype purified,
inactivated virus (PIV) vaccines. In addition, in formulation with an aluminum hydroxide
adjuvant, these vaccines elicit virus-neutralizing antibodies in mice and rhesus macaques and
provide at least partial protection against virus challenge [22].
4.2.3. Recombinant subunits
Recombinant subunit-based vaccines may prove to be significantly advantageous compared to
other approaches currently being implemented for development of a dengue vaccine. First of
all, the lack of a replicating virus helps to ensure the safety of the product by avoiding the
possibility for inadequate attenuation or reversion in the context of live virus approaches, or
inadequate inactivation in the context of killed virus vaccines. Furthermore, under a tetrava-
lent formulation, the ability to induce a balanced immune response may be more easily
manipulated through dose adjustments using recombinant subunits compared to four repli-
cating viruses. Finally, in terms of yield and cost effectiveness, and since the dengue vaccine
mainly targets developing areas, a high yielding, highly immunogenic, recombinant subunit
could prove to be an attractive alternative to vaccines based on virus replication, (live attenu-
ated or killed) where yields may be lower than required [23].
Recombinant subunit vaccines stand as one of the safest alternatives, as a means to bypass the
issue of viral interference, offering the possibility to administer a tetravalent formulation on an
accelerated schedule. An advantage of an accelerated schedule is that full protective immunity
could be induced more quickly, thus avoiding the potential of exacerbated disease due to partial
immunity during an extended immunization course. Among other advantages of an accelerated
schedule are better general compliance, more suitability for travelers and military personnel,
easier integration into existing immunization schedules, and the potential for use in an outbreak
setting. A balanced tetravalent immune response may also be more readily accomplished
through simple dose adjustments for each of the four recombinant proteins, in comparison to live
virus vaccines where the interactions between viruses can be complex and unpredictable [24].
4.2.4. Virus-like particles (VLPs)
VLP vaccines are virus-like particles that do not contain replicative genetic material, but permit
presentation of antigen in a repetitive, ordered array similar to the virion structure, which is
thought to increase immunogenicity [25]. Thus, the safety concerns of virus vaccines regarding
reversion mutants and immunocompromised individuals are obviated. The recombinant of
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VLP allows these vaccines to be usually manufactured large-scale in a cost-effective manner,
following current good manufacturing practices. They induce quick and fulminant humoral
immune responses by displaying antigens in an ordered and repetitive way. Their particulate
nature and dimensions allows an efficient assimilation by dendritic cells (DCs) and transpor-
tation to lymph nodes, followed by presentation and induction of optimal immune responses.
VLPs are renowned for inducing rapid and strong antibody responses. This trait is attributed
to their dense, highly repetitive, quasi-crystalline structures [26], see Dengue vaccine candi-
dates in Table 1.
Candidate name/
identifier
Antigen Vaccination Developer Preclinical Phase I Phase II Phase III
CYD Live recombinant
based on a yellow
fever vaccine 17D
backbone
DENV-1-4 prM/E 3 doses
(0/6/12 months)
Sanofi Pasteur X X X X
TV003/TV005
Tetravalent live,
attenuated/
recombinant (whole
virus DENV1–3 and
recombinant DENV2
in DENV4 backbone)
DENV-1,3,4
whole genome,
DENV-2 prM/E
1 dose US National
Institutes of
Health and
Butantan (with
licenses to
other
manufacturers)
X X X X
DENVax Tetravalent
live, attenuated/
recombinant (whole
virus DENV2 and
recombinant DENV1/
3/4 in DENV2
backbone)
DENV-2 whole
genome, DENV-1,
-3, -4 prM/E
2 doses (0/
90 days)
Takeda X X X
DPIV Tetravalent
purified inactivated
vaccine
DENV-1–4 whole
genome
2 doses (0/
28 days)
GSK/US
WRAIR/
Fiocruz
X X
DEN-80ETetravalent E
protein subunit
vaccine
Soluble DEN 1/2/
3/4 prM/E protein
3 doses (0/1/
2 months)
Merck X X
TVDVTetravalent
“shuffled” prM/E
expressed from
plasmid vector DNA
vaccine
Plasmid DNA
expressing DENV
1/2/3/4 prM-E
3 doses (0/1/
3 months)
US Naval
Medical
Research
Center
X X
TLAV-TPIV
Heterologous prime-
boost with live-
attenuated tetravalent,
live-attenuated
vaccine and
tetravalent alum-
adjuvanted purified
inactivated vaccine
Purified
inactivated
DENV or plasmid
vector expressing
prM/E (prime)
and live-
attenuated DENV
(boost)
US WRAIR X X
Dengue vaccine candidates; adapted from Kirsten et al. [27].
Table 1. Dengue vaccine candidates.
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4.3. Vaccines under clinical trials
4.3.1. CYD-TDV Dengvaxia
Sanofi Pasteur’s CYD vaccine is a live-attenuated tetravalent chimeric vaccine. In this vaccine,
the premembrane and envelope proteins from a wild-type dengue virus corresponding to each
of the four serotypes are substituted into the yellow fever (YF) 17D vaccine backbone. A strong
neutralizing antibody response to DENV2 was elicited in the first CYD clinical trial in healthy
adults, which evaluated only the serotype 2 vaccine strain. Participants previously given YF
vaccine seroconverted to all four dengue serotypes [28]. The first licensed dengue vaccine, a
live, attenuated, tetravalent dengue vaccine (CYD-TDV; Dengvaxia), has recently been regis-
tered in 15 countries as a three-dose immunization schedule administered subcutaneously at 6-
month intervals [29]. In the case of Dengvaxia, vaccination of children with no previous
infection (seronegative) may mimic an initial infection during the first step in the development
of ADE. Because vaccine protection is incomplete and unequal against the four serotypes, a
natural infection later in life can complete the sequence of events, causing ADE and severe, life-
threatening dengue fever [30].
Following CYD-TDV introduction, it should be administered as a three-dose series given on a
0-/6-/12-month schedule. However, additional evidence is required in order to determine
whether equivalent or better protection may be obtained through simplified schedules. In
response to a delay in a vaccine dose for any reason, the vaccine course should be resumed
(not restarted), maintaining the 6-month interval between subsequent doses. Given the 12-
month duration of the immunization schedule and to enable better vaccine monitoring, coun-
tries should have vaccine tracking systems implemented. CYD-TDV is not recommended for
use in children under 9 years of age, consistent with current labeling, in view of the association
of CYD-TDV with increased risk of hospitalized and severe dengue illness in the 2- to 5-year
age group. The target age for routine vaccination should be defined by each country, intended
to maximize the vaccination impact and programmatic feasibility of targeting specific age
groups. For instance, some countries may present the highest incidence of dengue illness
among the adult age population and may consider vaccinating people up to 45 years of age in
routine programs. The implementation of a routine CYD-TDV vaccination program at 9 years
of age in settings meeting the criteria mentioned above is expected to contribute to a 10–30%
reduction in symptomatic and hospitalized dengue illness over 30 years [31], see Table 2. This
vaccine will be reviewed further in a separate section since, differently to other vaccines in this
section, Dengvaxia has already been registered.
4.3.2. TV003 and TV005 Dengue vaccine
The Laboratory of Infectious Diseases at the U.S National Institutes of Health has evaluated
numerous monovalent and tetravalent dengue candidate vaccines to identify candidates with
the most acceptable safety, infectivity, and immunogenicity profile. Among these, TV003 is an
admixture of four live-attenuated recombinant dengue vaccine candidate viruses (rDEN1D30,
rDEN2/4D30, rDEN3D30/31, and rDEN4D30) [36]. Various monovalent candidates were ini-
tially tested in Phase 1 trials in order to optimize each of the four vaccine virus strains. Vaccine
virus serotypes 1, 3, and 4 are based on complete viruses, while serotype 2 is a recombinant
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virus based on the serotype 4 vaccine strain with the structural proteins replaced by those of
serotype 2. A single dose of TV005 elicits seroconversion rates above 90% against each sero-
type, and 90% of flavivirus-naive recipients displayed a tetravalent response. TV003 or TV005
has been licensed to several manufacturers, including Butantan, VaBiotech, andMerck. Phase 2
studies are underway in Brazil and Thailand, and a Phase 3 trial led by Butantan began in
February, 2016, in Brazil [27], see Table 3.
4.3.3. DENVax
Takeda’s live tetravalent dengue vaccine (TDV) candidate is based on a molecularly character-
ized attenuated serotype 2 strain (TDV-2). The DENV-2 PDK-53 virus was initially obtained
through 53 serial passages of the wild-type (wt) DENV-2 16681 in primary dog kidney (PDK)
Reference Lead
author /year
Conclusion
Four-year safety follow-up of the tetravalent dengue
vaccine efficacy randomized controlled trials in Asia
and Latin America,
Arredondo-
García et al.
2018 [32]
Data from the clinical trials for up to year 4 after
first vaccination indicate a positive benefit–risk
profile for the CYD-TDV vaccine for the
population aged 9 years old.
A multi-country study of dengue vaccination
strategies with Dengvaxia and a future vaccine
candidate in three dengue-endemic countries:
Vietnam, Thailand, and Colombia.
Lee et al. 2018
[33]
Given the absence of efficacy and half-life data
for any of the second-generation vaccine
candidates, it was assumed that NVC is 80%
efficacious with a half- life of 8 years.
Dengue vaccination during pregnancy—an overview
of clinical trials data.
Skipetrova
et al. [34]
In the small dataset assessed, no evidence of
increased adverse pregnancy outcomes has
been identified from inadvertent immunization
of women in early pregnancy with CYD-TDV
compared with the control group.
The conclusions are limited to vaccination in
CYD-TDV in the first trimester, since no data
are available on pregnancy outcome for
administration of this vaccine in the second or
third trimester. The data described here, and
those continuing to emerge from the on-going
clinical development and post-marketing of
CYD-TDV, provide a valuable contribution to
the currently limited available information on
the use of the dengue vaccine in pregnant
women.
Live-attenuated, tetravalent dengue vaccine in
children, adolescents and adults in a dengue-endemic
country: Randomized controlled phase I trial in the
Philippines.
Capeding et al.
2011 [35]
The safety profile of TDV in a flavivirus
endemic population was consistent with
previous reports from flavivirus-naïve
populations. A vaccine regimen of either three
TDV vaccinations administered over a year or
two TDV vaccinations given more than
8 months apart resulted in a balanced antibody
response to all four dengue serotypes in this
flavivirus-exposed population, including
children.
Table 2. Some CYD-TDV Dengue vaccine safety and immunogenicity studies in different populations.
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cells. The DENV-2 PDK-53 virus has proved to be safe, well-tolerated, immunogenic, and
elicits long-term humoral and cellular immune responses to DENV-2, based on clinical trials
conducted in the United States and Thailand [38]. Three chimeric strains (TDV-1, TDV-3, and
TDV-4) were engineered by substituting the premembrane (prM) and envelope (E) structural
genes of the respective DENV strains into the attenuated TDV-2 backbone [39]. TDV is
designed to promote humoral and cellular protective immune responses against all four
dengue serotypes, as it contains the premembrane and envelope proteins unique to each
serotype. These specific proteins are needed to induce neutralizing antibodies. The use of
DENV-2 as a backbone for TDV may confer additional protection against dengue. In particu-
lar, TDV contains the genes encoding the conserved nonstructural (NS) proteins within the
dengue backbone; and these proteins have been shown to be important in generating T-cell-
mediated responses to dengue infection. Furthermore, anti-NS1 antibodies have been associ-
ated with cross-protective humoral immune responses [40]. Table 4 shows some of the studies
conducted to determine the effectiveness of this vaccine.
4.3.4. DPIV tetravalent purified inactivated vaccine
The Walter Reed Army Institute of Research (WRAIR) in collaboration with GlaxoSmithKline
Vaccines (GSK) developed a live-attenuated tetravalent dengue virus vaccine candidate
comprised of four live virus strains representing each of the four DENV types. These strains
were attenuated by serial passage in primary dog kidney (PDK) cells [44]. The US Navy
Naval Medical Research Center (NMRC) has developed a tetravalent DNA vaccine (TVDV),
formulated with Vical’s Vaxfectin adjuvant, containing genes encoding the premembrane
(prM) and envelope (E) proteins for all four serotypes of dengue virus. Both Vaxfectin-
formulated and unformulated vaccines are currently being evaluated in Phase I human
testing [45].
Inactivated vaccines are assumed to provide acceptable safety profiles across a wide age range
as well as in immunocompromised hosts. In addition, these can be co-administered with other
vaccines. Shortened vaccination schedules and rapid immunization are also feasible using this
type of vaccines. For these reasons, a safe and efficacious tetravalent DENV PIV could be
suitable for national immunization programs across broad age ranges and baseline health
Reference Lead
author /year
Conclusion
In a randomized trial, the live-attenuated tetravalent
dengue vaccine TV003 is well- tolerated and highly
immunogenic in subjects with flavivirus exposure
prior to vaccination
Whitehead
et al. 2017
[37]
In summary, the authors demonstrated that the NIH
tetravalent dengue vaccine TV003 is well-tolerated
in flavivirus-experienced individuals and elicits
robust post-vaccination neutralizing antibody titers.
The live-attenuated dengue vaccine TV003 elicits
complete protection against dengue in a human
challenge model
Kirkpatrick
et al. 2016
[36]
TV003 induced complete protection against
challenge with rDEN2Δ30 administered 6 months
after vaccination. TV003 will be further evaluated in
dengue-endemic areas.
Table 3. Some TV003 vaccine safety and immunogenicity studies.
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status, as well as an active immunization option for travelers and military personnel, and a
potential tool for outbreak response [46]. Table 5 shows several DPIV vaccine safety and
immunogenicity studies.
Reference Lead
author /year
Conclusion
Safety and immunogenicity of a live-attenuated
tetravalent dengue vaccine candidate in flavivirus-
naive adults: a randomized, double-blinded Phase 1
clinical trial
George et al.
2015 [41]
TDV was generally well-tolerated, induced trivalent
or broader neutralizing antibodies to DENV in most
flavivirus-naive vaccines, and is undergoing further
development.
Safety and immunogenicity of a recombinant live-
attenuated tetravalent dengue vaccine (DENVax) in
flavivirus-naive healthy adults in Colombia: a
randomized, placebo-controlled, phase 1 study
Osorio et al.
2014 [42]
The authors emphasize the acceptable tolerability
and immunogenicity of the tetravalent DENVax
formulations in healthy, flavivirus-naive adults.
Further clinical testing of DENVax in different age
groups and in dengue-endemic areas is warranted.
Development of DENVax: A chimeric dengue-2
PDK-53-based tetravalent vaccine for protection
against dengue fever
Osorio et al.
2011 [43]
The DENVax vaccine is considerably different from
previously tested tetravalent vaccines in that all four
strains contain the same attenuating mutations as the
DEN-2 PDK-53 strain, a strain that has been shown
to be both safe and immunogenic in humans. Such
vaccine is critically needed to protect people from the
threat of dengue infection and improve public health
worldwide.
Table 4. Some TDV(DENVax) vaccine safety and immunogenicity studies.
Reference Lead
author /year
Conclusion
Phase I randomized study of a tetravalent dengue
purified inactivated vaccine in healthy adults from
Puerto Rico.
Diaz et al.
2018 [47]
Results from this first phase I study of a new vaccine
candidate with inactivated DENV in a dengue-
primed population showed that all four DPIV vaccine
formulations were well-tolerated and immunogenic.
This new investigational DPIV vaccine had an
acceptable safety profile in a small number of
flavivirus-primed healthy adult subjects and all
formulations boosted neutralizing antibodies (Nab)
responses, with complex adjuvants increasing
immunogenicity versus alum adjuvantation. Nab
titers remained high (and above baseline titers)
through M13. These results encourage continuation
of DPIV clinical development.
Phase 1 randomized study of a tetravalent dengue
purified inactivated vaccine in healthy adults in the
United States
Lepine et al.
2017 [48]
All DPIV formulations were well-tolerated. No
vaccine-related serious adverse events were observed
through 12 months after the second vaccine dose. In
all DPIV groups, geometric mean antibody titers
peaked at Day 56, waned through 6 months after the
second vaccine dose, and then stabilized. In the nine
subjects where boosting was evaluated, a strong
anamnestic response was observed. These results
support continuation of the clinical development of
this dengue vaccine candidate.
Table 5. Some DPIV vaccine safety and immunogenicity studies.
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4.3.5. DEN 80E vaccine
This vaccine (developed by Hawaii Biotech and now licensed to Merck) is composed of a
recombinant truncated protein corresponding to 80% of the N-terminal DENV E protein
(DEN-80E). The C-terminal truncation of the E protein at amino acid 395 removes the mem-
brane anchor sequence of the protein, resulting in a recombinant E protein with improved
secretion, purification and immunogenicity. The DEN-80E protein for each of the four dengue
serotypes has been expressed in the Drosophila S2 expression system to produce a tetravalent
vaccine [49], which induces a high level expression of proteins of interest. Specifically, the
system was chosen to express a plasmid containing the prM and N-terminal 80% of the E gene
sequence of DENV-2. The resulting polyprotein undergoes cleavage by endogenous proteases
and the 80E protein with a native-like N terminus is released. Two doses of the DENV-2
subunit 80E protein were administered to rhesus macaques in combination with one of seven
different adjuvants at a 3-month dosing interval. Following this administration, animals were
challenged with wild-type DENV-2 2 months after the last dose of vaccine. Neutralizing
antibodies were detected in all study animals after the first dose and this response was boosted
by the second dose. The highest neutralizing antibody titers were produced by the r80E
protein formulated with the adjuvants AS05 or AS08, and protection against viremia was
correlated with a higher neutralizing antibody titer at challenge. The same system was
employed to generate recombinant subunit E proteins (80E) of the other DENV serotypes. A
tetravalent formulation of the recombinant 80E proteins was evaluated in mice and nonhuman
primate experiments. In some instances, the NS1 protein of DENV-2 was included in the
formulation to potentially enhance the immune response to the vaccine. Macaques were
immunized with the tetravalent formulation four times (day 0, 28, 67, and 102) and were
challenged 5 months after the last dose. Due to the limited number of monkeys in each group,
monkeys were only challenged with DENV-2 or DENV-4. Monkeys developed a robust neu-
tralizing antibody response to all four DENV serotypes and were completely protected from
DENV-2 challenge [50]. Table 6 shows some of the studies conducted to determine the effec-
tiveness of this vaccine.
4.3.6. TVDV tetravalent “shuffled” prM/E expressed from a plasmid vector DNA vaccine
The U.S. Naval Medical Research Center (NMRC) developed a tetravalent plasmid DNA
vaccine candidate using prM and E protein genes expressed in a plasmid vector. A DENV-1
monovalent candidate of this vaccine was evaluated for safety and immunogenicity through a
phase I clinical trial on healthy flavivirus-naïve adults using a three-dose schedule at 0/1/
5 months. The results showed poor immunogenicity. Although it is possible that TVDV may
have a role as a travel vaccine in the future, the available data is currently insufficient to
anticipate its potential use as a travel vaccine [52].
The TVDV is a mixture of equal amounts of four monovalent double-stranded plasmid
DNA vaccines produced under current Good Manufacturing Practices conditions in the
United States. Each monovalent plasmid contains the prM and E genes of dengue 1, 2, 3, or
4 viruses cloned into the backbone plasmid VR1012 (Vical Incorporated, San Diego, CA)
[53]. Table 7 shows some of the studies conducted to determine the effectiveness of this
vaccine.
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4.4. Vaccine candidates under preclinical assays
There are numerous vaccine candidates that are being studied in preclinical trials, as can be
seen in Table 8.
4.4.1. EDIII-p64k fusion proteins and EDIII-capsid fusion proteins expressed in E. coli
Te Pedro Kourí Tropical Medicine Institute (IPK) in collaboration with the Center for Genetic
Engineering and Biotechnology (CIGB) in Cuba have led the development of various recom-
binant subunit vaccine candidates. One approach is based on fusion of DENV EDIII to the
carrier protein p64k of Neisseria meningitidis, and this EDIII-p64k fusion protein is then
expressed in E. coli. Evaluations in mice showed that monovalent vaccine candidates for all
Reference Lead author/
year
Conclusion
Preclinical development of a dengue tetravalent
recombinant subunit vaccine: Immunogenicity and
protective efficacy in nonhuman primates
Govindarajan
et al. 2015 [51]
Overall, the subunit vaccine was demonstrated to
induce strong neutralization titers resulting in
protection against viremia following challenge
even 8–12 months after the last vaccine dose.
The development of recombinant subunit
envelope-based vaccines to protect against dengue
virus induced disease
Coller et al.
2011 [24]
The DEN-80E recombinant subunit proteins for all
four dengue virus types are expressed at high levels
and have been shown to maintain native-like
conformation. When formulated with a variety of
adjuvants the antigens are potent immunogens and
induce high titer virus-neutralizing antibody
responses. Furthermore, the antigens have been
shown to protect against viral challenge in both
mouse and nonhuman primate models. Tetravalent
vaccine formulations have also been evaluated in
preclinical models with no evidence of immune
interference or competition between the four DEN-
80E antigens being observed. These proofs of
concept preclinical studies led to the advancement
of a monovalent DEN1-80E vaccine candidate into
clinical testing.
Development of a recombinant tetravalent dengue
virus vaccine: immunogenicity and efficacy studies
in mice and monkeys
Clements
et al. 2010 [23]
The production of recombinant dengue 80E
proteins in Drosophila S2 cells that are capable of
eliciting potent immune responses in mice and
nonhuman primates represents a major
achievement in the effort to develop a recombinant
dengue vaccine. The S2 cell expression system
efficiently produces 80E from all four dengue
serotypes. Our data show that co-administration of
the subunits from the four serotypes results in a
balanced immune response, equivalent to that
observed when the four individual components are
administered separately. Furthermore this response
can be induced in a relatively short period of time
(2–3 months).
Table 6. Some DEN 80E Vaccine safety and immunogenicity studies.
Dengue Fever - a Resilient Threat in the Face of Innovation160
DENV serotypes were able to induce neutralizing antibodies and protect against viral chal-
lenge. DENV-1 and DENV-2 monovalent candidates have also been evaluated in NHPs.
Monkeys were immunized subcutaneously with four doses of the monovalent vaccine (50–
100 g protein per dose, formulated in Freund’s adjuvant), which proved to be immunogenic
and provided protection against viral challenge. Adjuvants suitable for human use are under
evaluation, including N. meningitidis serogroup A capsular polysaccharide (CPSA) adsorbed
on aluminum hydroxide [25].
5. Final thoughts
Finally, we want to reflect on the implications of the co-circulation of the dengue virus and the
Zika virus, as well as on the new indications for the use of the Dengvaxia vaccine.
First, we will analyze the fact that the appearance of the infection by the Zika virus (another
flavivirus) in zones of high prevalence for dengue constitutes an interesting challenge for the
development of the ideal vaccine for both viruses.
5.1. Zika virus infection means new challenges in dengue vaccine development
Among pathogenic human flaviviruses, DENV and ZIKV are most closely related to each
other, with 55.1–56.3% amino acid sequence identity. Zika virus is closer to dengue virus than
to any of the other flaviviruses and indeed is almost close enough to think of it as a fifth
serotype [10]. Accordingly, emerging literature indicates many similarities between these two
viruses in terms of interactions between the virus and host immune system. For both viruses,
the interferon system is the central mediator of host defense and target of a viral counterattack,
Reference Lead author/
year
Conclusion
Safety and immunogenicity of a tetravalent dengue
DNA vaccine administered with a cationic lipid-
based adjuvant in a Phase 1 clinical trial
Thomas et al.
2018 [53]
TVDV-Vaxfectin was safe and well-tolerated in this
early Phase 1 human clinical trial. Whereas anti-
dengue IFNγ T-cell responses occurred in most of
the study subjects, anti-dengue neutralizing
antibody responses were poor. Utilization of
alternative delivery methods as well as examining
prime-boost approaches may result in a more
robust and long-lasting humoral immune response.
A dengue DNA vaccine formulated with
Vaxfectin® is well-tolerated, and elicits strong
neutralizing antibody responses to all four dengue
serotypes in New Zealand white rabbits
Raviprakash
et al. 2012
[54]
The formulated vaccine and the adjuvant were
tested for safety and/or immunogenicity in New
Zealand white rabbits using a repeat dose
toxicology study. The formulated vaccine and the
adjuvant were found to be well-tolerated by the
animals. Animals injected with formulated vaccine
produced strong neutralizing antibody response to
all four dengue serotypes.
Table 7. Some TVDV vaccine safety and immunogenicity studies.
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whereas complex interplays between antibody and T cell responses likely determine the
outcome of infection in flavivirus immune settings [55]. Dejnirattisai et al. found that most
mAbs to DENV also bound to ZIKV, yet the antibodies targeting the major linear fusion-loop
epitope (FLE) did not neutralize ZIKV, whereas they showed neutralizing activity against
DENV. ZIKV virus infection was found to be potently enhanced by DENV-immune plasma
and mAbs to DENV, suggesting the possibility that preexisting immunity to DENV might
increase ZIKV replication; thus, this data indicate that immunity to DENV might drive greater
ZIKV replication and have clear implications for disease pathogenesis and future vaccine pro-
grams for ZIKV and DENV [11]. There have been safety concerns related to Dengvaxia
resulting from long-term vaccine trials. In patient groups under 9 years of age, hospitalization
from DENV infection was greater for vaccinated children than for the nonvaccinated control
group. These findings suggest ADE of infection in DENV naive children at the start of the
study trial and who had been primed by but not protected by the vaccine. Consequently, the
vaccine is not licensed for use in children under 9 years of age and, furthermore, it is
recommended for use only in populations with a seroprevalence of 70% or greater of prior
DENV exposure in the age group to be vaccinated [56].
Techonological
approach
Antigen Vaccine developer Valency under
evaluation or
evaluated in NHP
Recombinant
subunit vaccines
EDIII-p64k fusion proteins and EDIII-capsid
fusion proteins expressed in E. coli
IPK/CIGB Monovalent
Bivalent 80E-STF2 fusion proteins expressed in
baculovirus/insect cells
VaxInnate Tetravalent
Tetravalent consensus EDIII protein expressed in
E. coli.
NHRI Tetravalent
DNA vaccine prM/E expressed from plasmid vector DNA
vaccine
US CDC Tetravalent
VLP Vaccines EDIII-HBsAg VLPs or ectoE-based VLPs
expressed in P. pastoris
ICGEB Tetravalent
Virus-vectored
vaccines
Tetravalent EDIII and DENV-1 ectoM expressed
from live-attenuated measles virus vector
Themis Bioscience/Institut X
Pasteur
Tetravalent
E85 expressed from single-cycle VEE virus vector Global Vaccines Tetravalent
Purified
inactivated virus
vaccine
Psoralen-inactivated DENV US NMRC Monovalent
Purified
inactivated
DENV
Purified inactivated DENV WRAIR/GSK/FIOCRUZ Tetravalent
Inactivated virus (+VEE-particle adjuvant) Global Vaccines Tetravalent
Live-attenuated
virus vaccines
DEN/DEN chimeric viruses, live, attenuated Chiang Mai University/
Mahidol X University/
NSTDA/BioNet-Asia
Monovalent
DEN host range mutations Arbovax Tetravalent
Table 8. Active dengue vaccine candidates in preclinical development that have been evaluated in NHP models.
Dengue Fever - a Resilient Threat in the Face of Innovation162
Currently, there is a high pressure to produce a vaccine against ZIKV, and in this context, the
extensive serological cross-reaction between DENV and ZIKV must be considered. It is likely
necessary that the vaccine be used in areas with high seroprevalence for DENV and raising de
novo ZIKV-neutralizing responses in such a setting might be challenging. It is likewise possi-
ble that vaccination of DENV-naive subjects against ZIKV might promote ADE of DENV
infection and, conversely, that vaccination against DENV might promote ADE of ZIKV infec-
tion. In summary, cross-reaction of antibodies to DENV with ZIKV and promotion of ADE
of infection can occur due to the existing similarities between the two viruses, even though
ZIKV differs in sequence identity from DENV by around 41–46% (in the sequence of the
envelope protein). In this context, ZIKV could be considered a fifth member of the DENV
serocomplex, a factor that must be considered in vaccine approaches to these two viruses [11].
The results of Barba-Spaeth group suggest that the epitope targeted by the EDE1 bnAbs
is more adequate for developing an epitope-focused vaccine for viruses of the ZIKV/DENV
super serogroup than is the FLE, which induces poorly neutralizing and strongly infection-
enhancing antibodies [57].
5.2. The Dengvaxia future
Dengvaxia is the only vaccine licensed to date for use in humans, which is why epidemiolo-
gists, health professionals, clinical physicians, and basic researchers (virologists, immunolo-
gists, molecular biologists, etc.) should be concerned about the future of this vaccine, which
has had a reverse according to the latest publications of its results, so we will end this chapter
with the following reflection based on the publications from 2016 to date.
Since April 2016, Dengvaxia has been licensed for use in 19 countries, and was recommended
by the WHO Strategic Advisory Group of Experts (SAGE) on immunization to be used in
regions with high endemicity, as defined by a prevalence of dengue antibodies of more than
50% in the targeted age group of people aged 9–45 years. Nevertheless, Guiar’s mathematical
model finds that a significant reduction of hospitalizations can be only achieved when the
vaccine is directed exclusively to seropositive individuals [58]. Along this same line, this
group of researchers in 2017 predicted a significant reduction in dengue virus infection-
related hospital admissions resulting from the administration of Dengvaxia only to dengue
seropositive individuals, based on the analysis of an age-structured model using the available
vaccine trial data. Moreover, the researchers predicted a significant increase in the number of
dengue-related admissions, over a 5-year period, if the vaccine is to be administered without
previous population screening for serostatus. The take-home message is that individual
serostatus is the most important feature when implementing this vaccine and that only
individuals of any age who have experienced at least one dengue virus infection will benefit
from vaccination [59, 60]. New data by Sanofi in November 2017 showed that Dengvaxia
could increase the risk of severe dengue in people who had not been previously exposed to
the virus. For any countries considering vaccination as part of their dengue control program,
the WHO recommends a “prevaccination screening strategy,” in which only dengue seropos-
itive people are vaccinated. The prescreening process could be achieved by conventional
serological testing for dengue virus to identify people who have had previous dengue infec-
tions. As Sanofi stated, “We are confident in Dengvaxia’s safety and its proven potential to
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reduce dengue disease burden in endemic countries. We will continue to work with the
international public health community and endemic countries, to ensure the best usage of
the vaccine to increase protection for populations at risk of subsequent dengue infections [that
are] potentially more debilitating” [61].
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